| Metric | Value (₹ Cr) | vs Q2 FY26 |
|---|---|---|
| Revenue | 423.15 | 23.1% |
| Total Income | 456.68 | 23.7% |
| Expenditure | 300.84 | 18.4% |
| PBT | 130.47 | 43.2% |
| Net Profit | 92.82 | 46.5% |
| OPM | 31.15% | 8.47pp |
| NPM | 20.32% | 8.67pp |
| EPS | 1.65 | 46.6% |
Anthem Biosciences Reports ¥15,134 Mn Revenue in IMFY26 with 24.8% PAT Margins
05 Feb 2026 · 5 Feb, 1:50 pm
Summary
Anthem Biosciences Limited, a CRDMO, announced its unaudited results for the third quarter and period ended December 31, 2025. The company reported a revenue from operations of ¥4,232 Mn for Q3FY26 and ¥15,134 Mn for 9MFY26. The EBITDA for Q3FY26 was ¥1,907 Mn and for 9MFY26 was ¥6,712 Mn. The PAT for Q3FY26 was £928 Mn and for 9MFY26 was ¥74,020 Mn. The company's CRDMO specialty ingredients contributed ¥4,719 Mn to the total revenue for 9MFY26.
Key Highlights
- 1
Revenue from Operations for Q3FY26: ¥4,232 Mn
- 2
Revenue from Operations for 9MFY26: ¥15,134 Mn
- 3
EBITDA for Q3FY26: ¥1,907 Mn
- 4
EBITDA for 9MFY26: ¥6,712 Mn
- 5
PAT for Q3FY26: £928 Mn
- 6
PAT for 9MFY26: ¥74,020 Mn
- 7
CRDMO Specialty Ingredients revenue for 9MFY26: ¥4,719 Mn
Management Comments
Not Provided
Not Provided
Informational and educational content only. Not investment advice.